Literature DB >> 2106048

Changes in the hormone receptors of human breast carcinoma xenografts in nude mice by treatment with cytotoxic agents.

J Koh1, E Shiina, Y Hosoda, M Hashimoto, O Yamamoto, S Sakai, T Kubota, K Enomoto, O Abe.   

Abstract

We examined the effect of chemotherapeutic agents on the estrogen receptors (ER) of breast carcinomas in vivo using human breast carcinoma strains (Br-10, T-61) serially transplanted into nude mice. When the tumor size reached approximately 1 X 1 X 1 cm, mitomycin C (MMC) at doses of 1, 2 and 4.5 mg/kg and cyclophosphamide (CPA) at a dose of 120 mg/kg, were administered once intraperitoneally, and the ERs of the tumors were measured sequentially by the dextran-coated charcoal method. Four days after the MMC administration at above doses, the binding sites of ER in Br-10 were not reduced and binding affinity was not affected. When the changes in ER content with time after the treatment with 4.5 mg/kg MMC and 120 mg/kg CPA were investigated, the ER content was found to be stable until 4 days after the treatment with both drugs, although the growth of T-61 had been significantly inhibited by the drugs. From these findings, it seems reasonable to initiate chemotherapy before endocrine therapy, since the chemotherapeutic agents did not reduce the ER content of the breast cancer strains.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2106048     DOI: 10.1007/bf02470719

Source DB:  PubMed          Journal:  Jpn J Surg        ISSN: 0047-1909


  19 in total

1.  Experimental chemotherapy of carcinoma of the human stomach and colon serially transplanted in nude mice.

Authors:  T Kubota; Y Shimosato; K Nagai
Journal:  Gan       Date:  1978-06

2.  Hormone dependency of a serially transplantable human breast cancer (Br-10) in nude mice.

Authors:  S Hirohashi; Y Shimosato; T Kameya; K Nagai; R Tsunematsu
Journal:  Cancer Res       Date:  1977-09       Impact factor: 12.701

3.  Treatment of metastatic breast cancer in estrogen receptor positive patients. A randomized trial comparing tamoxifen alone versus tamoxifen plus CMF.

Authors:  W R Bezwoda; D Derman; N G De Moor; M Lange; J Levin
Journal:  Cancer       Date:  1982-12-15       Impact factor: 6.860

4.  CMF versus CMF plus tamoxifen in advanced breast cancer in postmenopausal women. An EORTC trial.

Authors:  H T Mouridsen; T Palshof; E Engelsman; R Sylvester
Journal:  Eur J Cancer       Date:  1980       Impact factor: 9.162

5.  Oestrogen and progesterone receptors and response to endocrine therapy in Japanese breast cancer.

Authors:  Y Nomura; O Takatani; H Sugano; K Matsumoto
Journal:  J Steroid Biochem       Date:  1980-05       Impact factor: 4.292

6.  Ten-year experience with CMF-based adjuvant chemotherapy in resectable breast cancer.

Authors:  G Bonadonna; P Valagussa; A Rossi; G Tancini; C Brambilla; M Zambetti; U Veronesi
Journal:  Breast Cancer Res Treat       Date:  1985       Impact factor: 4.872

7.  Chemoendocrine therapy vs chemotherapy alone for advanced breast cancer in postmenopausal women: preliminary report of a randomized study.

Authors:  C G Kardinal; M C Perry; V Weinberg; W Wood; S Ginsberg; R N Raju
Journal:  Breast Cancer Res Treat       Date:  1983       Impact factor: 4.872

8.  Chemotherapy versus combination of chemotherapy and endocrine therapy in advanced breast cancer. A prospective randomized study.

Authors:  G Cocconi; V De Lisi; C Boni; P Mori; P Malacarne; D Amadori; E Giovanelli
Journal:  Cancer       Date:  1983-02-15       Impact factor: 6.860

9.  Adjuvant therapy of stage II breast cancer: 48-month follow-up of a prospective randomized clinical trial.

Authors:  C A Hubay; O H Pearson; J S Marshall; T A Stellato; R S Rhodes; S M DeBanne; J Rosenblatt; E G Mansour; R E Hermann; J C Jones; W J Flynn; C Eckert; W L McGuire
Journal:  Breast Cancer Res Treat       Date:  1981       Impact factor: 4.872

10.  [Experimental chemo- and chemoendocrine therapy of human breast carcinomas serially transplanted into nude mice].

Authors:  J Koh
Journal:  Nihon Geka Gakkai Zasshi       Date:  1988-01
View more
  1 in total

1.  Recombinant human interferon-alpha 2a increases hormone receptor level of a human breast carcinoma xenograft in nude mice and enhances the anti-proliferative activity of tamoxifen.

Authors:  K Josui; T Kubota; M Kitajima
Journal:  Jpn J Cancer Res       Date:  1992-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.